Bipartisan legislative momentum and expanding litigation are accelerating PBM-focused reform at federal and state levels, ...

Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefit RALEIGH, N.C., April 20, 2026 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas ...

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology and immunology therapies, announced IMULDOSA® (ustekinumab-srlf) is now covered by ...

Express Scripts agreed to pay a $1.5 million administrative penalty and implement corrective actions following an investigation by the West Virginia Offices of the Insurance Commissioner. Between May ...

On February 4, 2026, the Federal Trade Commission (FTC) proposed to settle its enforcement action against leading pharmacy benefit manager (PBM) Express Scripts, going beyond the insulin products that ...

The MarketWatch News Department was not involved in the creation of this content. Nation's largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates ...

Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. NEW YORK--(BUSINESS WIRE)--Today, Bernstein Litowitz Berger & ...

Nation’s largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers. Today, Bernstein Litowitz Berger & Grossmann LLP (BLB&G) ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

The Federal Trade Commission has reached a landmark settlement with Express Scripts, one of the nation’s largest pharmacy benefit managers, requiring sweeping changes aimed at lowering insulin costs ...

Express Scripts, a pharmacy benefit manager and subsidiary of Cigna (CI), has reached a settlement with the FTC over accusations that it artificially inflated the prices of insulin drugs, violating ...